对KCNQ1变异的遗传特征改善了1型长QT综合征患者的风险分层
Charles Morgat1, Véronique Fressart2, Alessandra Pia Porretta1,3
1CNMR Maladies Cardiaques Héréditaires Rares, APHP, Hôpital Bichat, 46 rue Henri Huchard, 75018 Paris, France.
概括
与其他1型长QT综合征 (LQT1) 患者相比,Jervell和Lange-Nielsen综合征 (JLNS) 变体的异构体载体患心脏事件的风险较低. 基因因素,如突变位置影响KCNQ1变种携带者的事件风险.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 遗传性心律失常综合征 遗传性心律失常综合征
背景情况:
- KCNQ1基因突变是QTc延长的主要原因,导致危及生命的心律失常.
- 第1型长QT综合征 (LQT1) 是由异合突变引起的,而同合突变会导致更高风险的Jervell和Lange-Nielsen综合征 (JLNS).
研究的目的:
- 调查异合体患者中KCNQ1变异的明显表现型表达.
- 根据LQT1和JLNS患者的遗传呈现来评估QTc持续时间和心脏事件发生率.
主要方法:
- 从遗传性心律失常诊所 (1993-2023) 获得的789名KCNQ1变体携带者的回顾性分析.
- 分类为JLNS,异构性JLNS (HTZ-JLNS) 和异构性非JLNS (HTZ-非JLNS) 组.
- 对JLNS变体,生存分析和多变量考克斯回归的文献综述.
主要成果:
- 对于HTZ-JLNS患者 (22%的异构体携带者),心脏事件的风险明显低于HTZ-Non-JLNS患者 (HR=0.34,P<0.01).
- 与HTZ-JLNS (441±32ms) 和HTZ-非JLNS (467±36ms) 相比,JLNS (551±54ms) 的平均QTc显著延长.
- 事件的独立风险因素包括毛孔局部化 (P<0.01),哈普隆缺陷 (P=0.04),C端局部化 (P=0.04) 和患者组 (P<0.01).
结论:
- 与其他LQT1患者相比,JLNS变体的异体携带者表现出心律不整事件的风险降低.
- 特定的遗传参数,包括突变的位置和类型,在KCNQ1变种携带者中显著影响心脏事件风险.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
969
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
969
Single Nucleotide Polymorphisms-SNPs
15.0K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.0K
Voltage-gated Ion Channels
8.2K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K


